BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240514T140000
DTEND;TZID=America/New_York:20240514T150000
DTSTAMP:20260405T102053
CREATED:20240410T142934Z
LAST-MODIFIED:20240410T142934Z
UID:46542-1715695200-1715698800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Hemophilia Alliance Network Services/Emerging Therapy Solutions
DESCRIPTION:Date: Tuesday\, May 14\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nHemophilia Alliance Network Services/Emerging Therapy Solutions \nA Gene Therapy Payer Contract \nWEBINAR DESCRIPTION:\nThe past twelve to eighteen months have been landmark times for gene therapy treatments for individuals with bleeding disorders.  While the third party payers\, reinsurers and prescription benefit plans have begun forming strategies for benefit plan coverage\, pricing\, patient qualifications and follow up reporting. Hemophilia Alliance Network Services (HANS) has been hard at work arranging for adequate contractual arrangements with important entities influencing Payor behavior and strategies for the use of Gene Therapy.  The HANS goal was to create relationships with entities that could offer acceptable contractual terms but importantly influence the common prior authorization process to provide a clear path for delivery of the product\, provision of the service to Hemophilia Treatment Center (HTC) patients\, and subsequent confidence in the payment for this high-cost therapy.   \nHANS is pleased to announce that it has executed an Agreement with Emerging Therapy Solutions (ETS) effective January 1\, 2024.  Emerging Therapy Solutions® (ETS)\, an industry leader in providing cutting-edge services to help payers and other risk-bearing entities prepare for the accelerating growth in cell and gene therapies and other high-cost\, complex treatments. This webinar will provide a high-level overview from HANS leadership regarding the Agreement with ETS as well as how HTCs can gain access to this Agreement.  HANS will ask the leadership from ETS to describe the business model and services they provide\, the ETS customer base and provide important information on how to HTCs can intersect with ETS to obtain necessary approvals for gene therapy treatments for qualified patients.  During this one-hour webinar you will hear important details on the authorization process\, clinical review and administrative details that provide a clearer path to benefit coverage and payment for HTC patients rather than the time-consuming process of single case agreements with payors that many HTCs have experienced thus far. \nThis webinar is available to ALL Hemophilia Treatment Centers that are members of the Hemophilia Alliance\, it is NOT restricted to participating members of the Hemophilia Alliance Network Services Agreements.  If an HTC is not a HANS member today and wishes to join HANS to access the ETS agreement \, please reach out to your Member and Community Relations Team Member who will assist you.  Administrators\, Finance team members\, Pharmacists and Physicians are ideal candidates to attend this webinar.  However\, it is open to any interested employee of member HTCs. \nSPEAKERS & BIOs:\n\nRoland Lamy\, Jr. – Vice President of Payer Relations\nRoland Lamy has held a variety of leadership positions in the healthcare industry including sales management\, underwriting\, employee benefit and rate development\, hospital and physician negotiations and contracting\, and government programs oversight and business management. Click here to learn more about Roland… \n\nZack Duffy – Director of Member & Community Relations\nMost recently\, Zack Duffy was the Program Administrator for The Hemophilia Center at Oregon Health & Science University (OHSU) overseeing the administrative and business functions of the clinic and pharmacy. He started with the Factor Program at The Hemophilia Center in 2013\, when it was a 340B physician dispense model. In 2017\, he led the transition from a physician dispense to a pharmacy dispensing model. Click here to learn more about Zack…
URL:https://hemoalliance.org/alliance-events/hemophilia-alliance-presents-hemophilia-alliance-network-services-emerging-therapy-solutions/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240515
DTEND;VALUE=DATE:20240518
DTSTAMP:20260405T102053
CREATED:20230908T175639Z
LAST-MODIFIED:20230908T175639Z
UID:65952-1715731200-1715990399@hemoalliance.org
SUMMARY:🟥 Member Event : 2024 Physical Therapists CE Conference
DESCRIPTION:Date: May 15 – 17\nLocation: Aurora\, CO \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/2024-physical-therapist-ce-conference-2/
LOCATION:Search
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240605T130000
DTEND;TZID=America/New_York:20240605T140000
DTSTAMP:20260405T102053
CREATED:20240513T202047Z
LAST-MODIFIED:20240513T202047Z
UID:65965-1717592400-1717596000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Wednesday\, June 5\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nWEBINAR OVERVIEW: \n\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from the 4th interim analysis of HEM-POWR\, a multinational\, open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi.\nThere will also be a review of the Q2 2024 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract.\n\nSPEAKER:\n\nDr. Vanessa K. Salinas-Lunas\nPediatric Hematology\nCenter for Inherited Blood Disorders \nSPEAKER’S BIO:\nN/A
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe-study-of-jivi/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240613
DTSTAMP:20260405T102053
CREATED:20230908T175404Z
LAST-MODIFIED:20240731T135554Z
UID:45495-1717977600-1718236799@hemoalliance.org
SUMMARY:🟥 Member Event : 2024 Nurses CE Conference
DESCRIPTION:Date: June 10 – 12\nLocation: Portland\, Maine
URL:https://hemoalliance.org/alliance-events/2024-nurses-ce-conference/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240620T140000
DTEND;TZID=America/New_York:20240620T150000
DTSTAMP:20260405T102053
CREATED:20240609T180107Z
LAST-MODIFIED:20240609T180107Z
UID:65966-1718892000-1718895600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts – Practice Considerations for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) from BioMarin
DESCRIPTION:Date: Thursday\, June 20\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTitle: Practice Considerations for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox)  \nObjectives:   \n\n\nReview coverage and typical prior authorization criteria for ROCTAVIAN\n\nReview considerations and pricing education available for single-case agreements\n\nHemophilia Alliance’s gene therapy support for Member Hemophilia Treatment Centers\n\nSpeakers: \n\n\nJosh Sammon\, PharmD\, Senior Director\, Market Access\, Hemophilia\n\nHemophilia Alliance Team
URL:https://hemoalliance.org/alliance-events/a-webinar-on-practice-considerations-for-roctavian-from-biomarin/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240625T130000
DTEND;TZID=America/New_York:20240625T140000
DTSTAMP:20260405T102053
CREATED:20240606T185838Z
LAST-MODIFIED:20240606T185838Z
UID:47764-1719320400-1719324000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts – Wilate Prophylaxis in VWD – Results from the WIL-31 Study from Octapharma
DESCRIPTION:Date: Tuesday\, June 25\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTitle: Wilate Prophylaxis in VWD – Results from the WIL-31 Study \nObjectives:\n1) Understand the bleeding symptoms experienced by folks with von Willebrand disease\n2) Understand the benefits of wilate prophylaxis in von Willebrand disease across different ages and types\n3) Understand the lack of von Willebrand factor and FVIII accumulation during wilate prophylaxis  \nSpeaker:\n\nClaudio Sandoval\nSenior Director of Scientific & Medical Affairs at Octapharma \nClaudio Sandoval is the Senior Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders\, cancer\, sickle cell disease\, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park\, NY and St. Jude Children’s Research Hospital in Memphis\, TN.
URL:https://hemoalliance.org/alliance-events/wilate-prophylaxis-in-vwd-results-from-the-wil-31-study-from-octapharma/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240711T130000
DTEND;TZID=America/New_York:20240711T140000
DTSTAMP:20260405T102053
CREATED:20240617T165403Z
LAST-MODIFIED:20240916T144535Z
UID:65967-1720702800-1720706400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Navigating Patient Assistance and Copay Assistance Schemes
DESCRIPTION:Date: Thursday\, July 11\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTitle:\nUnderstanding the difference between Copay Accumulators\, Copay Maximizers\, and Alternative Funding Programs. \nObjectives: \n\nIn this comprehensive session\, attendees will gain a deep understanding of three critical elements of the difference between patient access barriers: copay accumulators\, copay maximizers\, and alternative funding programs. This talk will demystify these concepts\, explain how each mechanism operates\, their impact on patients’ out-of-pocket costs\, and the broader implications for patients\, providers and insurers.\nBy the end of this session\, attendees will be equipped with the knowledge and tools to better understand the nuances of copay accumulators\, copay maximizers\, and alternative funding programs. They will leave with actionable strategies to support patients in managing their out-of-pocket costs while maintaining access to essential medications.\n\nSpeakers:\n\nBecky Burns\nCOO & CFO of the Bleeding and Clotting Disorders Institute\, Peoria\, IL. Click here to learn more about Becky. \n\nKollet Koulianos\nHemophilia Alliance Payer Relations Consultant. Click here to learn more about Kollet.
URL:https://hemoalliance.org/alliance-events/navigating-patient-assistance-and-copay-assistance-schemes/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240716T140000
DTEND;TZID=America/New_York:20240716T150000
DTSTAMP:20260405T102053
CREATED:20240629T004512Z
LAST-MODIFIED:20240629T004512Z
UID:65970-1721138400-1721142000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts – An interactive discussion on VWD case-based experience from Takeda
DESCRIPTION:Date: Tuesday\, July 16\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nDiscussion Topic: VWD Case-Based Experience \nDescription:\nJoin our expert\, Dr. Maissaa Janbain\, MD\, for an interactive discussion about managing patients who are living with VWD. Dr. Janbain will guide you through a VWD case-based experience\, including reviewing treatment history and discussing how VONVENDI [von Willebrand Factor (Recombinant)] may be used for on-demand treatment of gastrointestinal (GI) bleeding. \nSpeaker:\n\nMaissaa Janbain\, MD \nMaissaa Janbain\, MD is Currently an Associate Professor of Clinical Medicine at Tulane University; and serves as the Director of the Louisiana Center for bleeding and clotting disorders. Dr. Janbain has received multiple awards and grants (including National Hemophilia Foundation Fellowship Award 2014\, Louisiana Clinical and Translational Research Roadmap Scholarship 2015\, HTRS Mentored Research Award 2017 and School of Medicine Scientist Pipeline Program 2017) that allow her to focus her research and time on taking care of patients with benign hematologic disorders\, with an emphasis on bleeding disorders such as hemophilia and von Willebrand disease but also thrombosis and platelet disorders. She has presented at several national and international meetings and her research work has been published in several journals. Dr. Janbain is a founding member of the VENUS (venous thromboembolic network of the US) network and a member of the steering committee of ADVANCE US\, co- chairing the project sub-committee.
URL:https://hemoalliance.org/alliance-events/an-interactive-discussion-on-vwd-case-based-experience-from-takeda/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240821T130000
DTEND;TZID=America/New_York:20240821T140000
DTSTAMP:20260405T102053
CREATED:20240807T200904Z
LAST-MODIFIED:20240816T140453Z
UID:67941-1724245200-1724248800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Genetic Testing Program
DESCRIPTION:Date: Wednesday\, August 21\, 2024\nTime: 1:00pm – 2:00pm ET \n \n \n  \nTitle:\nHemophilia Alliance Genetic Testing Program \nHemophilia Alliance has introduced a new Genetic Testing Program as of August 1\, 2024. This initiative offers genetic testing for individuals with Hemophilia A\, Hemophilia B\, and von Willebrand’s disease. The program is specifically designed for patients receiving care at Hemophilia Alliance Member Treatment Centers who either lack insurance coverage\, are ineligible for other free genetic testing programs or studies\, or face prohibitive out-of-pocket costs. The testing will be conducted by Bloodworks in Washington state and Versiti in Wisconsin. \nWho will be eligible for free testing? \n\nPatients receiving care at a Hemophilia Alliance Member HTC who are not eligible for other available genetic testing free programs or studies AND meet one or more of the following criteria:\n\nPatient does not have insurance coverage.\nPatient does not have coverage for genetic testing under their insurance plan\, i.e. not a covered benefit.\nPatients who cannot afford the out-of-pocket expenses associated with the testing and are at\, or below\, 400% of the Federal Poverty Level.\n\n\n\nAdditional information on the program and how to get started can be found here.
URL:https://hemoalliance.org/alliance-events/hemophilia-alliance-genetic-testing-program/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240912
DTEND;VALUE=DATE:20240915
DTSTAMP:20260405T102053
CREATED:20240816T152754Z
LAST-MODIFIED:20240816T153134Z
UID:68243-1726099200-1726358399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 NBDF BDC
DESCRIPTION:Date: September 12 – 14\, 2024 (Atlanta\, GA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-nbdf-bdc/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240913
DTEND;VALUE=DATE:20240916
DTSTAMP:20260405T102053
CREATED:20240816T153430Z
LAST-MODIFIED:20240816T153430Z
UID:68248-1726185600-1726444799@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Foundation for Women & Girls with Bleeding Disorders
DESCRIPTION:Date: September 13 – 15\, 2024 (Long Beach\, CA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-foundation-for-women-girls-with-bleeding-disorders/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240922
DTEND;VALUE=DATE:20240925
DTSTAMP:20260405T102053
CREATED:20240816T153752Z
LAST-MODIFIED:20240816T153752Z
UID:68250-1726963200-1727222399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Self Insurance Institute of America Annual Conference
DESCRIPTION:Date: September 22 – 24\, 2024 (Phoenix\, AZ)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-self-insurance-institute-of-america-annual-conference/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240923
DTEND;VALUE=DATE:20240928
DTSTAMP:20260405T102053
CREATED:20231117T205255Z
LAST-MODIFIED:20240816T153146Z
UID:45993-1727049600-1727481599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Partners Physician Academy
DESCRIPTION:Date: September 23 – 27\, 2024 (Carmel\, IN)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/2024-partners-physician-academy/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241009
DTEND;VALUE=DATE:20241012
DTSTAMP:20260405T102053
CREATED:20230616T181031Z
LAST-MODIFIED:20241004T194904Z
UID:65944-1728432000-1728691199@hemoalliance.org
SUMMARY:🟥 Member Event : 2024 Fall Members Meeting
DESCRIPTION:Date: October 9 – 11\nLocation: New Orleans\, Louisiana \n  \n \n  \n\nTo download a copy DRAFT AGENDA\, click here.\nTo download a copy GLOSSARY 340B TERMS\, click here.\n\n  \nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/2024-fall-members-meeting/
LOCATION:New Orleans Marriott Warehouse Arts District Hotel\, 859 Convention Center Boulevard\, New Orleans\, LA\, 70130\, United States
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/06/FMMcalendaricon.png
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241017T120000
DTEND;TZID=America/New_York:20241017T130000
DTSTAMP:20260405T102053
CREATED:20240903T193616Z
LAST-MODIFIED:20240916T145026Z
UID:68579-1729166400-1729170000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Shining a Spotlight: The Journey to Optimize Care in Women and Girls with Hemophilia A
DESCRIPTION:Date: Thursday\, October 17\, 2024\nTime: 12:00pm – 1:00pm ET \n\n \nTopic: \nShining a Spotlight: The Journey to Optimize Care in Women and Girls with Hemophilia A \nObjectives: \n\nShine a light on the topic of women & girls with Hemophilia A\nDiscuss the complexities in the diagnosis of women & girls with Hemophilia A\nReview real-world experiences of women & girls with Hemophilia A\n\n  \nSpeaker: \nAngela Weyand\, MD Co-director\, Hemophilia Treatment Center\, Clinical Associate Professor of Pediatrics\, University of Michigan C.S. Mott Children’s Hospital \n \nDr. Weyand is pediatric hematologist/oncologist from University of Michigan C.S. Mott Children’s Hospital where she is a clinical associate professor. She received her medical degree from U of Michigan and did her residency in Seattle Children’s Hospital\, her fellowship at U of Michigan and her post doc in Hemophilia and Bleeding Disorders with the National Hemophilia Foundation Fellowship Program. \nShe has a particular interest in adolescent girls with bleeding and clotting disorders and issues impacting their care including quality of life.
URL:https://hemoalliance.org/alliance-events/shining-a-spotlight-the-journey-to-optimize-care-in-women-and-girls-with-hemophilia-a/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/06/Sanofi-New-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241020
DTEND;VALUE=DATE:20241023
DTSTAMP:20260405T102053
CREATED:20240816T154743Z
LAST-MODIFIED:20240816T154743Z
UID:68256-1729382400-1729641599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Advanced Topics I Nursing
DESCRIPTION:Date: October 22 – 22\, 2024 (Indiana\, IHTC)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-advanced-topics-i-nursing/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241022
DTEND;VALUE=DATE:20241024
DTSTAMP:20260405T102053
CREATED:20240816T154255Z
LAST-MODIFIED:20240816T154255Z
UID:68254-1729555200-1729727999@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 ATHN Data Summit
DESCRIPTION:Date: October 22 – 23\, 2024 (Atlanta\, GA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-athn-data-summit/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241025
DTEND;VALUE=DATE:20241026
DTSTAMP:20260405T102053
CREATED:20240816T154047Z
LAST-MODIFIED:20240816T154047Z
UID:68252-1729814400-1729900799@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 NBDF Red Tie Soiree
DESCRIPTION:Date: October 25\, 2024 (Chicago\, IL)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-nbdf-red-tie-soiree/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241030T130000
DTEND;TZID=America/New_York:20241030T140000
DTSTAMP:20260405T102053
CREATED:20241014T140040Z
LAST-MODIFIED:20241021T131441Z
UID:68994-1730293200-1730296800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Navigating The Enhanced Requirements Of DSCSA As A 340B Covered Entity
DESCRIPTION:Date: Wednesday\, October 30\, 2024\nTime: 1:00pm – 2:00pm ET \n \nTitle: \nNavigating The Enhanced Requirements Of DSCSA As A 340B Covered Entity \nObjectives: \n\nReview a brief history of the Drug Supply Chain Security Act and the new enhanced requirements.\nUnderstand where covered entities and their affiliated contract pharmacies fit into the supply chain.\nDiscuss the applicable requirements and potential pathways to compliance.\n\n  \nSpeaker: \nMichael Fusaro\, PharmD \nHead of Regulatory Compliance & Senior Pharmacist\, The Alliance Pharmacy \n \nMichael has over 10 years of experience as a pharmacist working with the bleeding disorder community and as the son of a hemophiliac\, a lifetime of personal experience. He graduated St. John’s University with his PharmD. in 2008. \nAs the Director of Regulatory Compliance & Senior Pharmacist of The Alliance Pharmacy (TAP)\, Michael oversees the revision and implementation of policies and procedures to ensure compliance with local\, state\, and federal laws as well as meeting the standards of our numerous accreditations. Michael maintains active pharmacist licenses in 12 states including New York where he resides.
URL:https://hemoalliance.org/alliance-events/navigating-the-enhanced-requirements-of-dscsa-as-a-340b-covered-entity/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2024/10/Mike-Fusaro-bio.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241106T140000
DTEND;TZID=America/New_York:20241106T150000
DTSTAMP:20260405T102053
CREATED:20241010T193249Z
LAST-MODIFIED:20241016T175406Z
UID:68958-1730901600-1730905200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - Explore KOVALTRY® With Confidence by Bayer
DESCRIPTION:Date: Wednesday\, November 6\, 2024\nTime: 2:00pm – 3:00pm ET (Updated Starting Time) \n\n \nTopic: \nExplore KOVALTRY® With Confidence \nOverview: \nClinical Trial Results\, Dosing and Pharmacokinetics of KOVALTRY® in adults\, adolescents and children \nSpeaker: \nMaissaa Janbain\, M.D.\, MSCR \nAssociate Director\, Louisiana Center for Bleeding and Clotting Disorders \nAssociate Professor of Medicine\, Tulane University New Orleans\, LA \n \nMaissaa Janbain\, MD.\, MSCR is Currently an Associate Professor of Clinical Medicine at Tulane University; and serves as the Director of the Louisiana Center for bleeding and clotting disorders. Dr. Janbain has received multiple awards and grants (including National Hemophilia Foundation Fellowship Award 2014\, Louisiana Clinical and Translational Research Roadmap Scholarship 2015\, HTRS Mentored Research Award 2017 and School of Medicine Scientist Pipeline Program 2017) that allow her to focus her research and time on taking care of patients with benign hematologic disorders\, with an emphasis on bleeding disorders such as hemophilia and von Willebrand disease but also thrombosis and platelet disorders. She has presented at several national and international meetings and her research work has been published in several journals. Dr. Janbain is a founding member of the VENUS (venous thromboembolic network of the US) network and a member of the steering committee of ADVANCE US\, co- chairing the project sub-committee.
URL:https://hemoalliance.org/alliance-events/membexplore-kovaltry-with-confidence-by-bayer/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2023/12/Bayer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241111
DTEND;VALUE=DATE:20241114
DTSTAMP:20260405T102053
CREATED:20240816T154945Z
LAST-MODIFIED:20240816T154945Z
UID:68258-1731283200-1731542399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Basic
DESCRIPTION:Date: November 11 – 13\, 2024 (Indiana\, IHTC)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-basic/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241116
DTSTAMP:20260405T102053
CREATED:20240816T155446Z
LAST-MODIFIED:20240816T155446Z
UID:68262-1731369600-1731715199@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Mountain States Hemostasis Network Regional Meeting
DESCRIPTION:Date: November 12 – 15\, 2024 (Girdwood\, AK)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-mountain-states-hemostasis-network-regional-meeting/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241114T180000
DTEND;TZID=America/New_York:20241116T153000
DTSTAMP:20260405T102053
CREATED:20230616T181218Z
LAST-MODIFIED:20241016T164021Z
UID:65945-1731607200-1731771000@hemoalliance.org
SUMMARY:🟥 Member Event : 2024 Medical Providers & Business Administrators Meeting
DESCRIPTION:Date: November 14 – 16\nLocation: Las Vegas\, Nevada \n \nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/2024-physicians-and-business-administrators-meeting/
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2024/07/hemo-meeting-000.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241115
DTEND;VALUE=DATE:20241119
DTSTAMP:20260405T102053
CREATED:20240816T155215Z
LAST-MODIFIED:20240816T155215Z
UID:68260-1731628800-1731974399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 NBDF Chapter Leadership Seminar
DESCRIPTION:Date: November 15 – 18\, 2024 (San Diego\, CA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-nbdf-chapter-leadership-seminar/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241118
DTEND;VALUE=DATE:20241121
DTSTAMP:20260405T102053
CREATED:20240816T155709Z
LAST-MODIFIED:20240816T155709Z
UID:68264-1731888000-1732147199@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 2024 Motivational Interviewing Workshop
DESCRIPTION:Date: November 18 – 20\, 2024 (Indiana\, IHTC)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-2024-motivational-interviewing-workshop/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241121T140000
DTEND;TZID=America/New_York:20241121T150000
DTSTAMP:20260405T102053
CREATED:20241022T140623Z
LAST-MODIFIED:20241022T140756Z
UID:69115-1732197600-1732201200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar On Health Equity From Takeda
DESCRIPTION:Date: Thursday\, November 21\, 2024\nTime: 2:00pm – 3:00pm ET \n \nTitle: \nHealth Equity \nDescription: \nPlease join Takeda for a webinar on Health Equity and how Takeda is making progress towards its goal of improving equitable access to treatment and care for all. Anthea will share Takeda’s broad strategy\, how it relates to bleeding disorders\, and offer opportunities for action to advance health equity goals. \nSpeaker: \nAnthea Cherednichenko\, VP US Hematology Franchise Head  \n \nAnthea leads the sales and marketing teams for Takeda’s Hematology portfolio. Anthea’s values aim to inspire positive patient outcomes through inclusive purpose-driven teams that drive innovation. Anthea previously served as the General Manager for Takeda Austria. Prior to that role\, she was in Global and European leadership roles in Hematology based out of Switzerland. Originally from Australia\, Anthea spent her early career years in medical device and health IT marketing roles in both Australia and Asia\, before joining Baxter (later acquired by Takeda) in 2013. Anthea holds a Master of Public Health from the University of Sidney and Master of Business Administration from Victoria University.
URL:https://hemoalliance.org/alliance-events/a-webinar-on-health-equity-from-takeda/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/06/Takeda-logo-new.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241204T120000
DTEND;TZID=America/New_York:20241204T130000
DTSTAMP:20260405T102053
CREATED:20241101T160243Z
LAST-MODIFIED:20241101T163332Z
UID:69334-1733313600-1733317200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Sanofi On Real World Surgical Experiences with Altuviiio
DESCRIPTION:Date: Wednesday\, December 4\, 2024\nTime: 12:00pm – 1:00pm ET \n \n  \n  \n  \n \nTopic: \nReal World Surgical Experiences with Altuviiio \nDescription: \nThis program will focus on sharing real-world experiences with Altuviiio\, especially within a surgical context. We’ll kick things off with an introduction to Altuviiio\, followed by some in-depth discussions on surgical experiences. We’ll wrap up with a summary and a Q&A segment\, which I’m sure will spark some great conversations! \nSpeaker: \nShveta Gupta\, MD \n \nShveta Gupta\, MD\, is a Pediatric Hematologist Oncologist and Medical Co-Director at Alliance OBGYN. Dr. Gupta also serves a the Medical Director for IQVIA. \nDr. Gupta received her medical degree with honors and distinction from All India Institute of Medical Sciences in New Delhi\, India. She completed both an internship and residency in pediatrics at Children’s Hospital Los Angeles\, where she also completed a fellowship in hematology oncology. Her primary clinical interests include sickle cell disease as well as bleeding and clotting disorders\, including hemophilia and von Willebrand disease. In addition\, she pursued further training in transfusion medicine and coagulation disorders at Baylor College of Medicine in Houston where she acquired additional expertise in urgent hemotherapy and coagulation consultation in critically ill pediatric patients. \nIn 2016-2017\, Dr. Gupta served as chair of the Hemostasis and Thrombosis Research Society Fellows Network. She is a member of the American Society of Hematology\, the Hemostasis and Thrombosis Research Society\, and the American Association of Blood Banks.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-sanofi-on-real-world-surgical-experiences-with-altuviiio/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/06/Sanofi-New-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241211T130000
DTEND;TZID=America/New_York:20241211T140000
DTSTAMP:20260405T102053
CREATED:20241126T181513Z
LAST-MODIFIED:20241126T182239Z
UID:69641-1733922000-1733925600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from CSL Behring - Learn about HEMGENIX from the patient perspective
DESCRIPTION:Date: Wednesday\, December 11\, 2024\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nTOPIC: \nLearn about HEMGENIX from the patient perspective \nOBJECTIVE: \nMichael will share his personal experience after receiving HEMGENIX \nRECOMMENDED AUDIENCE: \nHTC providers\, social workers\, administration and support staff \nSPEAKER: \nMichael – Common Factors Advocate Hemophilia B \n \nMy Life at a Glance – At the age of four\, I was diagnosed with hemophilia B factor IX deficiency. My parents told me that this disorder would limit me and that I would most likely have to progress through life with caution. So\, at a very young age\, I was forced to make an adult decision. I had to either learn how to manage \n my hemophilia or accept the possible limitations that were awaiting a severe hemophiliac. When I was a kid\, I made sure to not let hemophilia get in the way by staying on top of managing it. It was hard to accept help from anyone because I wanted to do it on my own. It was my superpower\, not theirs. \nMy previous local support group was amazing. They organized scholarships and had activities that were safe for hemophilia patients. It was a close-knit community. I even volunteered there! After finding the right treatment for me\, I have noticed myself living a more stress-free lifestyle; I no longer have to infuse a minimum of twice a month to maintain my factor levels. \nMy Message to the Community – Hemophilia is our superpower. It’s time to don that cape and advocate for yourself.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-learn-about-hemgenix-from-the-patient-perspective/
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2023/12/CSL-Behring.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241217T150000
DTEND;TZID=America/New_York:20241217T160000
DTSTAMP:20260405T102053
CREATED:20241126T182846Z
LAST-MODIFIED:20241126T182846Z
UID:69645-1734447600-1734451200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Pfizer on HYMPAVZI: An anti-tissue factor pathway inhibitor
DESCRIPTION:Date: Tuesday\, December 17\, 2024\nTime: 3:00pm – 4:00pm ET \n \n  \n  \n  \n  \n \nTOPIC: \nHYMPAVZI: An anti-tissue factor pathway inhibitor \nOBJECTIVE: \nTo educate attendees on the novel mechanism of action of HYMPAVZI\, the Ph3 clinical trial results and indicated dosage and administration. \nINTENDED AUDIENCE: \nHCP \nSPEAKER: \nDr. Jennifer Schumacher\, PhD\, Senior Medical Director\, Hemophilia \n \nJennifer Schumacher Sr. Medical Director has over 21 years of Medical Affairs and Biotech Industry experience. Currently\, a senior medical director in hemophilia\, Jennifer is the US medical lead for marstacimab. During her tenure at Pfizer\, she has held several positions beginning in US Medical Affairs in Oncology and transitioning to medical director in Rare Disease where she has lead the global medical team for transthyretin amyloid (ATTR) cardiomyopathy and served as publications lead. Jennifer joined the US hemophilia medical team in 2023. \nJennifer received her PhD in Pharmacology from the University of Minnesota\, Minneapolis\, USA and a B.S. in Biotechnology and Chemistry from St. Cloud State University\, St. Cloud\, USA. \nJennifer is based in Minneapolis\, Minnesota and enjoys spending time with her husband and two children. She loves reading\, cooking and the great outdoors\, snowmobiling in the winter and spending time with family and friends at their cabin in the summer.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-on-hympavzi-an-anti-tissue-factor-pathway-inhibitor/
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2024/01/Pfizer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241218T130000
DTEND;TZID=America/New_York:20241218T140000
DTSTAMP:20260405T102053
CREATED:20241101T163407Z
LAST-MODIFIED:20241101T163925Z
UID:69340-1734526800-1734530400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Novo Nordisk - Unmet Needs in Current Hemophilia Care: From Burdens to Breakthroughs
DESCRIPTION:Date: Wednesday\, December 18\, 2024\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nTitle: \nUnmet Needs in Current Hemophilia Care: From Burdens to Breakthroughs \nDescription and Session Objectives: \nTo provide a clinical overview of the cost and treatment burden across all hemophilia types\, the experience with current therapy\, and unmet needs that may be addressed with novel therapies. \nTarget Audience: \nAll HTC Staff \nSpeakers: \nParin Chikani PharmD\, MBA \nRyan Rodriguez PharmD\, MS\, BCPS \n \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care. \n \nRyan Rodriguez is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders\, aligning with his passion for evidence-based patient care. Prior to joining Novo Nordisk\, Ryan earned his PharmD degree from the University of Florida\, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy\, where he also earned his Master’s degree in epidemiology. Throughout his career\, Ryan has been involved in medical communications\, evidence generation and publication\, and formulary management for various public and private entities.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-novo-nordisk-unmet-needs-in-current-hemophilia-care-from-burdens-to-breakthroughs/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/09/Standard-Manufacturing-Partners-Novo_width_191px.png
END:VEVENT
END:VCALENDAR